Cochrane for Clinicians
Putting Evidence into Practice
Copper Intrauterine Device vs. Depot Medroxyprogesterone Acetate for Contraception
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2011 Jan 1;83(1):35-36.
A 19-year-old nulliparous woman comes to the office to discuss contraceptive options. She previously used depot medroxyprogesterone acetate (Depo-Provera) but was bothered by the weight gain and spotting she attributed to the medication. She would like to know whether the copper intrauterine device (IUD) might be a more effective contraceptive option with fewer adverse effects.
What are the comparative benefits and harms of the copper IUD versus Depo-Provera?
The copper IUD is more effective in preventing pregnancy compared with Depo-Provera.1 Each contraceptive method has different adverse effects; the evidence is too limited to make comparisons of discontinuation rates. (Strength of Recommendation = B, based on inconsistent or limited-quality patient-oriented evidence)
Depo-Provera and the copper IUD are highly effective contraceptives. Depo-Provera is a common choice for young women because it does not require daily administration. Adverse effects include irregular vaginal spotting, amenorrhea, delayed return of fertility, nausea, weight gain, decreases in bone mineral density, and mood fluctuations, and it has the inconvenience of needing an office visit every three months for continued administration. Previously, IUD use was limited in young women because it was thought to increase the risk of pelvic infection. However, research has shown that the risk of pelvic inflammatory disease is only increased in the first month immediately after insertion.2 The American College of Obstetricians and Gynecologists supports IUDs as a contraceptive option in adolescents, citing no increase in the risk of sexually transmitted disease or pelvic inflammatory disease, or harms to future fertility.3 Copper IUD adverse effects include heavy menstrual bleeding and cramping, increased risk of pelvic infection for 20 days after insertion, insertion procedure risks (perforation, discomfort), and device expulsion. Nonsteroidal anti-inflammatory drugs reduce bleeding and cramping associated with IUD use.4 Alternatively, the hormonally impregnated IUD has the same pregnancy rate as the copper IUD and oral combined estrogen-progesterone contraceptives.5
The Cochrane authors reviewed two randomized controlled trials (n = 967) comparing the rates of discontinuation, unintended pregnancy, infection, and human immunodeficiency virus (HIV) infection at one- to two-year follow-up in women taking Depo-Provera or an oral contraceptive compared with women using the copper IUD.1 Both studies were done in developing countries. One of the studies only recruited women infected with HIV; these women had a 77 percent loss to follow-up in the IUD group, and participants were allowed to choose between hormonal methods (Depo-Provera versus oral contraceptives), making conclusions limited.
Based on the limited data from these two studies, the IUD is more effective than hormonal methods (Depo-Provera or oral contraceptive) at preventing pregnancy (risk ratio = 0.45; 95% confidence interval, 0.24 to 0.84). Conflicting results were seen for discontinuation rates: one trial showed a higher discontinuation rate in the Depo-Provera group, whereas the other trial (which allowed women to choose and switch between Depo-Provera and oral contraceptives) showed a higher discontinuation rate in the copper IUD group. Participants infected with HIV were less likely to experience HIV or AIDS disease progression (including death) in the IUD group than in the Depo-Provera group (risk ratio = 0.58; 95% confidence interval, 0.39 to 0.87). There was no statistically significant difference in the incidence of pelvic inflammatory disease, which was low in both groups.
In generalizing this review's results to U.S. primary care settings, the higher rates of effectiveness for the copper IUD, which requires less patient adherence, should not be surprising to physicians. However, mixed findings regarding discontinuation rates and a possible decrease in HIV progression should be interpreted with caution because of the short follow-up periods (one to two years), heterogeneous populations (women with and without HIV infection), and high loss to follow-up in one of the trials.
Background: Highly effective contraception is essential to reduce unintended pregnancies and the effect these pregnancies have on individual persons, society, and public health resources. Intrauterine devices (IUDs) and depot medroxyprogesterone acetate (Depo-Provera) are two commonly used long-acting, reversible contraceptive methods with different risk and benefit profiles.
Objectives: To compare the contraceptive and noncontraceptive benefits and risks of using the copper IUD versus Depo-Provera.
Search Strategy: In June 2009, the authors searched the Cochrane Pregnancy and Childbirth Group Trials Register, the Cochrane Central Register of Controlled Trials, PubMed, Popline, Clinical Trials.gov, the Current Controlled Trials metaRegister, EMBASE, and LILACS, and contacted study authors.
Selection Criteria: Randomized trials comparing women using copper IUDs with women using Depo-Provera.
Data Collection and Analysis: The authors assessed eligibility and trial quality, and extracted and double-entered data.
Main Results: Two studies were included in the review. In the one study of women who were infected with human immunodeficiency virus (HIV), the IUD was compared with Depo-Provera or the oral contraceptive, according to the women's choice. Because the majority of women chose Depo-Provera, the authors have included this study in the review, within a mixed hormonal contraception subgroup.
Overall, the copper IUD was more effective than Depo-Provera or hormonal contraception at preventing pregnancy (risk ratio = 0.45; 95% confidence interval, 0.24 to 0.84). HIV disease progression was reduced in the IUD group (risk ratio = 0.58; 95% confidence interval, 0.39 to 0.87). There was no significant difference in pelvic inflammatory disease rates between the two groups. Discontinuation of the allocated method was less frequent with the IUD in one study, and less frequent with hormonal contraception in the other study (in which women were allowed to switch between various hormonal methods).
Authors' Conclusions: In the populations studied, the IUD was more effective than hormonal contraception with respect to pregnancy prevention. High-quality research is urgently needed to compare the effects, if any, of these two commonly used contraception methods on HIV acquisition or seroconversion and HIV and AIDS disease progression.
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org).
REFERENCESshow all references
1. Hofmeyr GJ, Singata M, Lawrie TA. Copper containing intra-uterine devices versus depot progestogens for contraception. Cochrane Database Syst Rev. 2010;(6):CD007043....
2. Meirik O. Intrauterine devices—upper and lower genital tract infections. Contraception. 2007;75(6 suppl):S41–S47.
3. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol. 2007;110(6):1493–1495.
4. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst Rev. 2006;(4):CD006034.
5. French R, Sorhaindo AM, Van Vliet HA, et al. Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception. Cochrane Database Syst Rev. 2010;(2):CD001776.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Dr. Guirguis-Blake presents a clinical scenario and question based on the Cochrane Abstract, followed by an evidence-based answer and a critique of the review. The practice recommendations in this activity are available at http://www.cochrane.org/reviews/en/ab007043.html.
The series coordinator for AFP is Kenny Lin, MD, Department of Family Medicine, Georgetown University School of Medicine, Washington, DC.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions